Abstract:

Purpose: This study aims to investigate the effectiveness and safety of omalizumab in the clinical environment in patients with chronic spontaneous urethra resistant to antihistaminic therapy. Remedies and Methods: The records of 30 patients followed due to CSA, who were not responded to an antihistaminic treatment for more than 6 months and who were given omalizumab treatment were reviewed backward. Those who have no urticular plaque and swelling are fully responded, those who have improved quality of life according to the beginning of treatment and have a noticeable recovery in their symptoms are partially responded, those who have no recovery in their symptoms are regarded as unresponsive.  Results: Patients treated with omalizumab (women/man: 23/7) were taken to the study. The average time of treatment with omalizumab was 10.3±4.8 (min-max:3-21) months. After treatment with Omalizumab, 4 (13.3%) patients received a full response, 26 (86.7%) patients received a part of the response, while no patient was able to respond. During the use of Omalizumab patients did not experience any serious side effects. Only one (3.3%) patients had local erythema.  The result: In this study, antihistaminic therapy resistant CSA has also shown that omalizumab is an effective and safe treatment.

Keywords: